NextCell Pharma

Second quarter (2022-12-01 until 2023-02-28)

• Operating income amounted to 2,734 (1,840) TSEK, of which Cellaviva counted for 2,106 (1,279) TSEK.
   
• Operating result amounted to -11,408 (-10,212) TSEK.
   
• Earnings per share* amounted to -0.33 (-0.30) SEK.
   
• Cash and bank amounted to 77,617 (118,170) TSEK.
   
• Solidity** amounted to 89.3 (92.7) %

First half year (2022-09-01 until 2023-02-28)

• Operating income amounted to 5,747 (3,187) TSEK of which Cellaviva counted for 4,244 (2,616) TSEK.
   
• Operating result amounted to -20,327 (-16,684) TSEK.
   
• Earnings per share* amounted to -0.59 (-0.49) SEK.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2022/2023: 34,379,523 (34,379,523)
 shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (34,379,523) shares.
**Solidity: Own capital's share of the sheet total.

Significant events in the second quarter

• NextCell announced at the end of March that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in the phase II part of the childhood diabetes study.
• The company announced in mid-January that it had received positive comments and recommendations on the draft pediatric plan (PIP) previously submitted to the European Medicines Agency's pediatric unit (PDCO).
• NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by flu, RS and HMP virus.

Significant events after the reporting period

• NextCell announced at the end of March that the results of the clinical phase I/II study in type 1 diabetes had been accepted for publication in the peer-reviewed journal Diabetologia, the official journal of the European Association for the Study of Diabetes
• The company announced late April that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia.